Abpro Holdings, Inc.

Abpro Holdings, Inc. (Nasdaq: ABP) is a clinical-stage biopharmaceutical company that reached public markets through a SPAC business combination and operates in the biotechnology and antibody drug discovery sector. The company filed a 10-K/A amendment with the SEC on April 1, 2024, reflecting its status as a reporting public company following its de-SPAC transaction. Abpro focuses on developing bispecific and multispecific antibody therapeutics targeting oncology and other serious disease indications. The amended annual filing underscores the company's continued obligations as a post-combination registrant navigating the regulatory and disclosure requirements of public market participation. For full filing history, deal terms, and sponsor data on ABP, sign up for complete access at SpacDesk.